Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Shanghai OPM Biosciences Co's Revenue for the
three
months ended in Mar. 2026 was ¥182.2 Mil. Shanghai OPM Biosciences Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was ¥156.8 Mil.
Hence, Shanghai OPM Biosciences Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.16.
Shanghai OPM Biosciences Co (SHSE:688293) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Shanghai OPM Biosciences Co Receivables Turnover Related Terms
Shanghai OPM Biosciences Co Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai OPM Biosciences Co Receivables Turnover Chart
SHSE:688293 vs VRTX, REGN, RVMD: Receivables Turnover Comparison
For the Biotechnology subindustry, Shanghai OPM Biosciences Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai OPM Biosciences Co Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai OPM Biosciences Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Shanghai OPM Biosciences Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai OPM Biosciences Co (SHSE:688293) has a Receivables Turnover of 1.16 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shanghai OPM Biosciences Co and its competitors. According to the industry distribution chart, Shanghai OPM Biosciences Co ranks #573 out of 841 companies in the Biotechnology industry, placing it in the top 68.1%.
Is Shanghai OPM Biosciences Co's Receivables Turnover too high?
Shanghai OPM Biosciences Co's current Receivables Turnover is 1.16. The Biotechnology industry median Receivables Turnover is 5.28. Shanghai OPM Biosciences Co's value of 1.16 is 78% below this industry median. Based on the distribution chart, Shanghai OPM Biosciences Co ranks #573 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai OPM Biosciences Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai OPM Biosciences Co's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai OPM Biosciences Co ranks #573 out of 841 companies for Receivables Turnover. This places Shanghai OPM Biosciences Co in the lower half of its industry. The industry median Receivables Turnover is 5.28. Shanghai OPM Biosciences Co's value of 1.16 is 78% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.28, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai OPM Biosciences Co's current Receivables Turnover of 1.16 is 78% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Shanghai OPM Biosciences Co and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai OPM Biosciences Co's current Receivables Turnover is 1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai OPM Biosciences Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai OPM Biosciences Co (SHSE:688293) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥34.03, compared to a current price of ¥54.83 — trading 61.1% above its estimated fair value. The current Receivables Turnover is 1.16 and 78% below the Biotechnology industry median of 5.28. Shanghai OPM Biosciences Co's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Shanghai OPM Biosciences Co (SHSE:688293), the current Receivables Turnover is 1.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai OPM Biosciences Co (SHSE:688293) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai OPM Biosciences Co stock appears to be overvalued.
The current stock price of ¥54.83 is trading 61.1% above its estimated GF Value™ of ¥34.03.
GuruFocus considers Shanghai OPM Biosciences Co to be Significantly Overvalued.
Key valuation signals for SHSE:688293:
Receivables Turnover: 1.16
GF Value™: ¥34.03 vs. price of ¥54.83 (61.1% above fair value)
Industry Position: 78% below the Biotechnology median (#573 of 841)
No single metric tells the full story. See the SHSE:688293 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688293 has been successfully added to your 
